King’s College London
A Material Transfer Agreement (MTA) has been established to support the development of innovative chimeric antigen receptor T-cells (CAR-T) targeting the anti-integrin avb6 in the treatment of solid tumors. This groundbreaking approach involves the utilization of the anti-integrin avb6-specific peptide (A20) instead of scFv as a recognition element. The aim is to leverage this advancement for potential applications in Thai patients diagnosed with solid tumors.
John Maher
Qualification
- M.D., Ph.D.
Title and Affiliation
Lecturer/Senior Researcher/CSO
- CAR Mechanics Group, Guy's Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, UK.
- Department of Immunology, Eastbourne Hospital, Kings Drive, Eastbourne, UK.
- Leucid Bio Ltd., Guy's Hospital, Great Maze Pond, London, UK.
Email: [email protected]
Link: https://www.kcl.ac.uk/people/john-maher